First Patient Receives KSQ-004EX for Advanced Cancer
Source: Targeted Oncology, April 2025
A phase 1/2 trial evaluating KSQ-004EX, a novel CRISPR-engineered tumor infiltrating lymphocyte (eTIL) therapy, has dosed its first patient with an advanced solid tumor.
This first patient was enrolled by Rodabe Amaria, MD, professor of melanoma medical oncology and principal investigator of the study at The University of Texas MD Anderson Cancer Center.
“The promise of TIL therapy remains high, but current approaches fall short of addressing the needs of most patients with solid tumors. Preclinically, the combined inactivation of SOCS1 and Regnase-1 in KSQ-004EX strongly increased anti-tumor functionality. We believe these enhancements give KSQ-004EX the potential to significantly advance TIL therapy for the treatment of solid tumors,” said Qasim Rizvi, chief executive officer of KSQ and chief executive officer-partner at Flagship Pioneering, in a press release.